JPRN-UMIN000043840已完成未知
General Drug Use Surveillance (All-Patient Surveillance) of POLIVY for Intravenous Infusion 30mg and 140mg (polatuzumab vadotin [genetical recombination]) -Relapsed or refractory diffuse large B-cell lymphoma- - General Drug Use Surveillance (All-Patient Surveillance) of POLIVY for Intravenous Infusion 30mg and 140mg (polatuzumab vadotin [genetical recombination]) -Relapsed or refractory diffuse large B-cell lymphoma
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 1,877
研究概览
简要总结
The incidence rate of ADRs [95% confidence interval (CI)] in the safety analysis set (1827 patients) was 49.15% (46.83 -51.47 patients) (898 patients), and 2217 ADRs occurred.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"Peripheral T Cell LymphomaPediatric Hodgkin LymphomaNCT04213209Takeda95
招募中
不适用
General Drug Use Surveillance (All Patient Surveillance) of ENSPRYNG Syringes for Subcutaneous Injection - Prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica)JPRN-UMIN000041047Chugai Pharmaceutical Co. Ltd.330
已完成
不适用
PERJETA® IV Infusion Drug use surveillanceBreast CancerJPRN-UMIN000017699Chugai Pharmaceutical Co., Ltd.261
招募中
不适用
A Survey of Brentuximab Vedotin in Pediatric Participants with Hodgkin LymphomaHodgkin LymphomaJPRN-jRCT2031220244Contact for Clinical Trial Information8
已完成
不适用
Observational Data Analysis in EuroSIDA (MK-0518-058)HIV-1 InfectionsNCT01078233Merck Sharp & Dohme LLC6,617